This chapter presents two case studies and series of question and answers on hairy cell leukemia (HCL). It commences with a discourse on how minimal residual disease (MRD) defined, and also MRD on portend relapse in HCL, and ends with the question on best front-line therapy in a symptomatic pregnant patient with HCL. The chapter also discusses on whether a patient relapses after a single cycle of cladribine and best therapeutic approach, and best treatment for patients with multiply relapsed HCL and a role for hematopoietic cell transplantation (HCT).
- Hairy cell leukemia (HCL)
- Minimal residual disease (MRD)
ASJC Scopus subject areas